Knuff & Co LLC Cuts Stake in Bristol-Myers Squibb (NYSE:BMY)

Knuff & Co LLC lowered its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 33.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,798 shares of the biopharmaceutical company’s stock after selling 5,345 shares during the quarter. Knuff & Co LLC’s holdings in Bristol-Myers Squibb were worth $554,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. OFI Invest Asset Management purchased a new position in Bristol-Myers Squibb during the 3rd quarter valued at approximately $25,000. Milestone Investment Advisors LLC purchased a new position in Bristol-Myers Squibb during the 3rd quarter valued at approximately $27,000. Blue Bell Private Wealth Management LLC grew its holdings in Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 200 shares in the last quarter. Legacy Financial Group LLC purchased a new position in Bristol-Myers Squibb during the 3rd quarter valued at approximately $39,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb during the 4th quarter valued at approximately $40,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. BMO Capital Markets dropped their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. Barclays dropped their target price on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. Finally, Wells Fargo & Company lifted their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Stock Up 0.7 %

NYSE BMY traded up $0.29 on Friday, reaching $43.99. 12,104,489 shares of the stock traded hands, compared to its average volume of 14,314,010. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The company has a fifty day moving average price of $50.37 and a 200-day moving average price of $50.74. The company has a market cap of $89.17 billion, a price-to-earnings ratio of -14.19, a PEG ratio of 14.82 and a beta of 0.45. Bristol-Myers Squibb has a 12 month low of $43.33 and a 12 month high of $69.10.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The business had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 EPS. As a group, research analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were issued a $0.60 dividend. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.46%. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.